135889-00-8 Usage
Uses
Cefcapene is a metabolite of Cefcapene Pivoxil (C242550). Antibacterial, orally absorbed cephalosporin.
Definition
ChEBI: A cephalosporin compound having (carbamoyloxy)methyl and N-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino side-groups. It is used (generally as the corresponnding pivaloyloxymethyl ester prodrug) as an oral antibac
erial.
Antimicrobial activity
A semisynthetic cephalosporin formulated for oral administration
as the prodrug ester, cefcapene pivoxil. Activity and
uses are similar to those of cefditoren.
Available in Japan.
Check Digit Verification of cas no
The CAS Registry Mumber 135889-00-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,8,8 and 9 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 135889-00:
(8*1)+(7*3)+(6*5)+(5*8)+(4*8)+(3*9)+(2*0)+(1*0)=158
158 % 10 = 8
So 135889-00-8 is a valid CAS Registry Number.
InChI:InChI=1/C17H19N5O6S2/c1-2-3-8(9-6-30-16(18)20-9)12(23)21-10-13(24)22-11(15(25)26)7(4-28-17(19)27)5-29-14(10)22/h3,6,10,14H,2,4-5H2,1H3,(H2,18,20)(H2,19,27)(H,21,23)(H,25,26)/b8-3-/t10-,14-/m1/s1
135889-00-8Relevant articles and documents
Synthesis and structure-activity relationships of 7β-[(Z)-2-(2-aminothiazol-4-yl)-3-(substituted)-2- propenoyl-amino]-3-cephems with C-3 substitutions
Ishikura,Kuboto,Minami,Hamashima,Nakashimizu,Motokawa,Kimura,Miwa,Yoshida
, p. 466 - 476 (2007/10/02)
Synthesis and biological activity of a series of 7β-[(Z)-2-(2-aminothiazol-4-yl)-3-(substituted)-2- propenoylamino]-3-cephem-4-carboxylic acids with C-3 substitutions and their pivaloyloxymethyl esters are described. These acid compounds exhibited potent antibacterial activity against both Gram-positive and Gram-negative bacteria. Pivaloyloxymethyl esters of selected compounds in this series were found to be well absorbed from small intestine in mice. Pivaloyloxymethyl 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-pentenoylamino]-3- carbamoyloxymethyl-3-cephem-4-carboxyiate hydrochloride hydrate (S-1108) was finally selected as the candidate for clinical evaluation.
